Background
colorectal cancer, toxicity, cancer, cancer death, adenocarcinoma, deaths
CANCER, COLORECTAL CANCER, ADENOCARCINOMA, DISEASE PROGRESSION
Gastro-esophageal adenocarcinoma (GEA) is the fifth most common cancer worldwide, causing over one million new cases (1,033,701) each year and is the third-leading cause of cancer death (about 782,685 deaths and 8.2% of total in 2018) [At initial diagnosis more than two thirds of patients are not suitable for curative treatment, because they have an advanced stage GEA [In the long-term, nearly all patients fail to first line-line therapy and suffer from disease progression. Only 42%-54% of those patients receive another treatment regimen [Ramucirumab is an accepted second line therapy in advanced GEA either as monotherapy or in combination with paclitaxel [In the second-line setting Irinotecan as a monotherapy or in combination with 5-FU/Folinic Acid (FOLFIRI) is a safe and efficient regimen and has shown a significant improvement of OS compared to BSC for patients with progressive GEA [With regards to toxicity, additional support for the safety and efficacy of FOLFIRI in combination with ramucirumab (FOLFIRI‐Ram) was established in the RAISE trial in second-line advanced colorectal cancer after progression on 5-FU/Folinic acid and Oxaliplatin (FOLFOX) with bevacizumab [